We invest in KPTI because they have an enterprise value below $2 billion, and an approved oral blood cancer drug, XPOVIO (Selinexor), with a new mechanism of action and blockbuster potential. XPOVIO is likely to be approved in additional blood cancer indications this month/year. We are not ecstatic about KPTI because they are at a tough part of the life cycle of a smid-cap biopharma company, early commercial. This is a tough place in a typical time, not to mention in a pandemic and a drug with a new mechanism of action that will require more customer education.
Later this week, KPTI is presenting at ASCO with an investor event scheduled as well. In today's article we discuss KPTI's recent BOSTON data in more detail, with a comparison chart we created to some other approved relapsed/refractory myeloma drugs. You can access our article at this link: https://bit.ly/2XDeAl0. (Free sign-up required for access.)